Platelet function in lung cancer patients undergoing lobectomy

Hvas, Anne‐Mette; Vad, Henrik; Pedersen, Søren; Licht, Peter B.; Nybo, Mads; Hornbech, Kåre; Zois, Nora E.; Christensen, Thomas

doi:10.1080/00365513.2019.1663555

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in contrast to our expectations based on a previous study by Hvas et al, showing increased platelet aggregation in patients with operable lung cancer compared to healthy controls. 28 The stage of cancer in the study by Hvas et al is like the one in the present study, but Charlson Comorbidity Index was not calculated by Hvas et al, hence a strict comparison is therefore not possible.…”

Section: Discussionmentioning

confidence: 56%

Increased In Vivo Thrombin Generation in Patients with Localized Non-Small Cell Lung Cancer Unfit for Surgery

Højbjerg

Bentsen

Vinholt

et al. 2023

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Patients with lung cancer face a substantially increased risk of thromboembolic disease. Patients with localized non-small cell lung cancer (NSCLC) who are unfit for surgery due to age or comorbidity have additional thrombotic risk factors. Thus, we aimed to investigate markers of primary and secondary hemostasis, since this could assist in treatment decisions. We included 105 patients with localized NSCLC. Ex vivo thrombin generation was determined by calibrated automated thrombogram and in vivo thrombin generation was determined by measurement of thrombin–antithrombin complex (TAT) levels and prothrombin fragment F1 + 2 concentrations (F1 + 2). Platelet aggregation was investigated by impedance aggregometry. Healthy controls were used for comparison. TAT and F1 + 2 concentrations were significantly higher in NSCLC patients than in healthy controls ( P < .001). The levels of ex vivo thrombin generation and platelet aggregation were not increased in the NSCLC patients. Patients with localized NSCLC considered unfit for surgery had significantly increased in vivo thrombin generation. This finding should be further investigated as it could be relevant for the choice of thromboprophylaxis in these patients.

show abstract

Section: Discussionmentioning

confidence: 56%

Increased In Vivo Thrombin Generation in Patients with Localized Non-Small Cell Lung Cancer Unfit for Surgery

Højbjerg

Bentsen

Vinholt

et al. 2023

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

“… 43 Yet, the influence of platelet count on platelet aggregation results is minor when platelet count remains within the reference interval, which was the case in our study population. 44 Since elevated platelet count is common in lung cancer and it has previously been shown that platelet aggregation was significantly increased in patients with localized NSCLC prior to surgery compared to healthy individuals, 14 the decrease in platelet count and platelet aggregation seen in our study population may be due to SBRT. In order to elucidate different mechanisms of activation and to detect platelet inhibitors, various agonists were chosen.…”

Section: Discussionmentioning

confidence: 79%

“…[11][12][13] In addition, platelets are wellestablished contributors to the pathophysiology of cancer and thrombosis, why evaluation of platelet aggregation provides valuable information on the thrombotic risk profile of patients with cancer. [14][15][16] Different cancer treatment modalities have been proven to increase the risk of thromboembolism; however, knowledge of the impact of radiotherapy on the coagulation system is sparse. [17][18][19] Stereotactic body radiotherapy (SBRT) represents hypofractionated radiotherapy, delivering high doses of radiation to the tumor in few fractions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Stereotactic Body Radiotherapy on Thrombin Generation and Platelet Aggregation in Patients with Non-Small Cell Lung Cancer

Bentsen,

Hojbjerg,

Vinholt

et al. 2023

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Patients with localized non-small cell lung cancer (NSCLC) considered unfit for surgery are at substantially increased risk of venous thromboembolism. Radiotherapy may further increase this risk. We aim to investigate the impact of stereotactic body radiotherapy (SBRT) on thrombin generation and platelet aggregation. We included 110 patients with localized NSCLC treated with SBRT. Blood samples were obtained prior to SBRT, immediately after SBRT completion, and 4-6 weeks following SBRT. Ex vivo and in vivo thrombin generations were analyzed using a calibrated automated thrombogram and commercial enzyme-linked immunosorbent assays. Platelet aggregation was evaluated using multiple electrode aggregometry. No significant differences were found in ex vivo or in vivo thrombin generation between blood samples before and immediately after SBRT treatment. Platelet aggregation was lower immediately after SBRT than before SBRT (TRAP: P = 0.04 and ASPI: P = 0.02) but remained within the reference interval. SBRT did not affect in vivo and ex vivo thrombin generation or platelet aggregation. SBRT did not cause prothrombotic changes in the coagulation in this study population of SBRT-treated patients with localized NSCLC.

show abstract

Platelet function in lung cancer patients undergoing lobectomy

Cited by 2 publications

References 16 publications

Increased In Vivo Thrombin Generation in Patients with Localized Non-Small Cell Lung Cancer Unfit for Surgery

Increased In Vivo Thrombin Generation in Patients with Localized Non-Small Cell Lung Cancer Unfit for Surgery

Impact of Stereotactic Body Radiotherapy on Thrombin Generation and Platelet Aggregation in Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About